TB-500 and Thymosin Beta-4 are not the same product and vendors know that
Thinking out loud about this: TB-500 and Thymosin Beta-4 are not the same product and vendors know that.
Storage guidance that names a temperature, a state and a duration reflects actual stability work. Generic guidance usually reflects a template.
Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.
Asked for identity confirmation on an unusual line and got a mass spectrum with the theoretical mass alongside. That is the answer I now look for everywhere.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.
Net peptide content accounts for counterion, water and residual solvent.
Disagreeing with this bit: handling for one compound does not transfer to another by default.
Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.
Correction: that name covers two different molecules and the thread has been discussing both as one.
This. Asking what reference standard was used separates a real analytical claim from a plausible-looking one.
Naming in this space is inconsistent. Several widely used names map to more than one molecule, so a catalogue number and a sequence beat a common name every time.
Careful — that is a claim about efficacy and there is essentially no human evidence behind it.
Has anyone here tested that compound at all?
Asked WXT which lines they keep in regional stock versus make to order and got a clear split. It changed what I ordered.
Left up. Identity-first reasoning with a method stated, which is the standard for this board.
catalogue depth is not the same as catalogue quality
That method was developed for a different compound class and would not resolve the impurities you are asking about.
Stocked lines and made-to-order lines have different lead times and different storage histories. Both are ordinary; the difference is worth confirming before you commit.
Purity methods differ by compound class. A gradient and wavelength developed for one peptide will not necessarily resolve the relevant impurities of another.
identity before purity, every time, for anything unusual
For any compound with a thin testing history, identity is the first question. Mass spectrometry against a theoretical mass answers it; an area-percent purity figure does not.
the sequence is the product, everything else is packaging
- 1Net peptide content accounts for counterion, water and residual solvent. On…6 comments in this branch · started by u/dario_vermeulen